不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
tisagenlecleucel 对比真实世界标准治疗在复发/难治性滤泡性淋巴瘤中的有效性
英文原题：Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma.
查看英文原题
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目的
在复发/难治性滤泡性淋巴瘤中，将tisagenlecleucel的疗效与真实世界标准治疗（SoC）进行对比分析。
材料与方法
一项回顾性间接匹配比较研究，使用II期ELARA试验和美国Flatiron Health Research Database的数据。
结果
经比值加权后，tisagenlecleucel组与SoC组的完全缓解率分别为69.1%和17.7%，总缓解率分别为85.6%和58.1%。在总生存期方面，观察到tisagenlecleucel较SoC估计可降低死亡风险。tisagenlecleucel与SoC相比，无进展生存期的风险比为0.45（95% CI：0.26，0.88），至下一次治疗时间的风险比为0.34（95% CI：0.15，0.78）。
结论
观察到tisagenlecleucel较SoC在改善疗效终点方面呈现一致的趋势。
展开英文摘要原文
Aim: To contextualize the effectiveness of tisagenlecleucel versus real-world standard of care (SoC) in relapsed/refractory follicular lymphoma. Materials & methods: A retrospective indirect matched comparison study using data from the phase II ELARA trial and the US Flatiron Health Research Database. Results: Complete response rate was 69. 1 versus 17. 7% and the overall response rate was 85. 6 versus 58. 1% in tisagenlecleucel versus SoC, post weighting by odds.
For overall survival, an estimated reduction in the risk of death was observed in favor of tisagenlecleucel over SoC. The hazard ratio for progression-free survival was 0. 45 (95% CI: 0. 26, 0. 88), and for time-to-next treatment was 0. 34 (95% CI: 0. 15, 0. 78) with tisagenlecleucel versus SoC. Conclusion: A consistent trend toward improved efficacy end points was observed in favor of tisagenlecleucel versus SoC.
论文信息
- 作者
- Hao Y、Hsu WC、Parzynski CS、Degtyarev E、Hampson LV、Masood A、Wu WH
- 第一作者单位
- Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.United States
- 通讯作者单位
- Genesis Research, Hoboken, NJ 07030, USA.United States
- 文献类型
- 非美国政府资助研究
- 期刊
- Journal of comparative effectiveness research2023 Jul
- 原文标识
- PubMed 37345672 · DOI 10.57264/cer-2022-0173
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →